354 Stock Chart & Stats
€22.20
-€0.20(-0.64%)
At close: 4:00 PM EDT
€22.20
-€0.20(-0.64%)
Day’s Range― - ―
52-Week Range€18.50 - €42.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€646.64M
Enterprise Value€2.24K
Total Cash (Recent Filing)€129.47M
Total Debt (Recent Filing)€857.79M
Price to Earnings (P/E)15.1
Beta0.71
Next Earnings
Nov 05, 2026EPS Estimate
1.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding32,555,614
10 Day Avg. Volume0
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio-3.13
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€42.24Price Target Upside90.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)6.41
Revenue Forecast (FY)€718.89M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow indicates that reported earnings are converting into liquidity, supporting debt service, reinvestment, and selective capital deployment. This cash-generation capability provides a durable financial foundation as Collegium integrates acquisitions and manages its product portfolio.
ADHD Franchise GrowthJornay PM is showing sustained prescription, revenue, prescriber, and market-share gains, demonstrating growing adoption rather than isolated sales improvement. Continued ADHD franchise expansion can diversify Collegium beyond opioid products and create a stronger platform for future commercial growth.
Azstarys Expansion PotentialThe Azstarys acquisition adds a newly commercialized growth product with early sales traction, increased guidance, and long-dated reported intellectual-property protection. Integration is complete and the expanded sales force should support broader prescriber coverage and a durable contribution to revenue.
Bears Say
Elevated LeverageDebt remains large relative to equity, leaving Collegium more sensitive to earnings volatility, refinancing conditions, and cash demands than a lightly leveraged company. Although leverage improved from prior years, the balance-sheet structure may constrain flexibility while acquisition benefits are being realized.
Opioid Portfolio PressureDeclines across two established pain products create a meaningful offset to ADHD growth and increase reliance on newer assets to sustain consolidated expansion. NUCYNTA is also facing authorized-generic pricing pressure, which can reduce net realizations and make the legacy portfolio less dependable.
Earnings Quality And Belbuca RiskThe divergence between improving adjusted results and a GAAP loss, together with the sizable EBITDA-to-EBIT gap, reduces confidence in the durability and visibility of reported earnings. Potential Belbuca generic entry could add a further structural challenge to an important pain franchise revenue stream.
Collegium Pharmaceutical News
354 FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was €18.50 and its highest was €42.00 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is €646.64M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Aug 06, 2026. The company reported €1.651 earnings per share for the quarter, beating the consensus estimate of €1.478 by €0.173.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.57.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,555,614 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of €1.651 in its last earnings report, beating expectations of €1.478. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in DE:354
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€42.24 (90.26% Upside)
€42.24 (90.26% Upside)
Blogger Sentiment
Bullish
DE:354 Sentiment 100%
Sector Average 63%
Sector Average 63%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
34.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
354 Company Deck
354 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.View all DE:354 earnings summaries354 Stock 12 Month Forecast
Average Price Target
€42.24
▲(90.26% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―